Beigene (NASDAQ:ONC) Trading 4.2% Higher – Should You Buy?

Beigene, Ltd. (NASDAQ:ONC)’s share price rose 4.2% on Friday . The stock traded as high as $274.00 and last traded at $273.67. Approximately 80,645 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 440,196 shares. The stock had previously closed at $262.60.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ONC. JMP Securities set a $348.00 price objective on Beigene in a research report on Friday, February 28th. Macquarie raised their price target on Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday, February 28th. Guggenheim reiterated a “buy” rating on shares of Beigene in a research note on Friday, February 28th. Sanford C. Bernstein set a $259.00 price objective on shares of Beigene in a research report on Thursday, March 13th. Finally, Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and upped their target price for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd.

Beigene Stock Up 2.1 %

The company has a market capitalization of $26.44 billion, a price-to-earnings ratio of -32.53, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72.

Beigene (NASDAQ:ONC) last posted its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The company had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.09 billion. As a group, research analysts expect that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, COO Xiaobin Wu sold 21,267 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of Beigene stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,052,367 shares of company stock valued at $270,454,249. Insiders own 7.43% of the company’s stock.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.